Phase 3 Readout~month
Phase 3 Topline: A Prospective, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and
- Company
- Mesoblast Limited (MESO)
- Indication
- Degenerative Disc Disease
Other upcoming events for MESO
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.